Clinical Trial Update: Impact of BMI on CDK4/6 Inhibitors Efficacy and Safety in Advanced Breast Cancer

View source ↗

Summary

A clinical trial update examining how body mass index may influence the effectiveness and safety of CDK4/6 inhibitors in patients with advanced breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CDK4/6 inhibitors

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Advanced Breast Cancer | Status: ACTIVE_NOT_RECRUITING